Khalid KamalAssociate Professor of Pharmacy Administration
Mylan School of Pharmacy and Graduate School of Pharmaceutical Sciences
Pharmaceutical, Administrative and Social Sciences
418B Mellon Hall
Education:Ph.D., Pharmacy Administration, West Virginia University, 2005
M.Pharm, Pharmacology, University of Bombay, 1996
B. Pharm, Pharmacy, University of Bombay, 1994
Khalid M. Kamal, PhD is an Associate Professor in the Division of Clinical, Social and Administrative Sciences at Duquesne University Mylan School of Pharmacy. He completed his Bachelors in Pharmacy (1994) and Masters in Pharmacology (1996) at Mumbai University, India and received his PhD in Health Outcomes Research (2005) from the Department of Pharmaceutical Systems and Policy, West Virginia University.
Dr. Kamal has been on the faculty of Duquesne University since 2005. He has been a Visiting Professor teaching pharmacoeconomics and decision modeling courses at institutions such as Kobe Gakuin University in Kobe, Japan and West Virginia University School of Pharmacy, Morgantown, WV. Dr. Kamal also completed the American Association of Colleges of Pharmacy Academic Leadership Fellows Program in 2014.
Dr. Kamal's primary research and teaching interests have been pharmacoeconomics, patient-reported outcomes research, and most recently, improving quality of care using real world data sources such as electronic medical records and specialty pharmacy data. Over the years, his research has focused on issues such as cost-effectiveness of treatments, quality of life, productivity costs, economic burden of diseases, and issues related to quality of care in chronic conditions such as rheumatoid arthritis, osteoporosis, prostate cancer, diabetes, multiple sclerosis, breast cancer, Parkinson's, and asthma.
Dr. Kamal's scholarship has yielded over 39 peer-reviewed publications and two research-based book chapters. He has also disseminated his work via 100 research presentations at national and international meetings. He has received internal and external grants to conduct research, serving in the capacities of both Principal and Co-Investigator. Among his awards are the 2010 School of Pharmacy Faculty award for outstanding contributions in teaching, research, and service; top poster award at the 2015 Annual Meeting & Expo of National Association of Specialty Pharmacy; second prize in the student research presentation category at the 2014 annual meeting of Drug Information Association (DIA); best paper award at the 2010 annual meeting of the Academy of Managed Care Pharmacy (AMCP) and the 2006 Association of Rheumatology Health Professionals Graduate Student Award.
#MeetTheProfessors YouTube Series: Dr. Khalid Kamal
|Course Title||Faculty Role||Typical Census||Years|
|Pharmacoeconomic Evaluations||100%||15 - 30||2006 - present|
|Patient-Reported Health Outcomes||100%||5 - 10||2006 - present|
|Research Methods in
|Course master (30%)
||5 - 10||2005 - present|
|Healthcare databases||20%||5 - 10||2015 - present|
|Collaborative Practice Agreements
to evaluate clinical services)
|50%||165+||2007 - present|
|American Healthcare System||30%||165+||2007 - present|
|Research Methods (Elective)||Course master (50%)
||5 - 10||2009 - present|
|Drug Literature Evaluation||(30%)||35 - 45||2006 - 2012|
|International Pharmacy - Japan||Summer trip (100%)||5 - 10||2010 - present|
|Health Outcomes Research Track for Pharm.D. Students
Designed to provide pharmacy students with the skills
necessary to quantify the "value" of pharmaceutical
treatments and services
Coursework (6 crs.), independent study (3 crs.)
|100%||2 - 3||2010 - present|
|Healthcare Supply Chain Management Program
(Offered through the School of Business)
American Healthcare System
|Team taught (33%)||10 - 15||2008 - present|
|The Faculty of Pharmaceutical Sciences,
Kobe-Gakuin University, Kobe, Japan
Pharmacoeconomics in the Japanese Healthcare System
|Department of Pharmaceutical Systems and Policy,
West Virginia University
Decision Analysis in Healthcare (Graduate Course)
|Visiting||5 - 10||Spring 2013, 2015, 2017|
|Pharmacoeconomic Evaluations (Graduate Course)||Visiting||5 - 10||Fall 2014|
CURRENT GRADUATE ADVISEES
8/2015 - Present
- Master's Thesis Committee Chair, Pratyusha Vadagam (Duquesne University). Cost of illness and pharmacoeconomic evaluation of new treatments in Cystic Fibrosis. Expected graduation - Fall 2017
- Master's Thesis Committee Member, Tyler Dunn (Duquesne University). The association between medication adherence in mental illness and substance use disorder relapse in dually-diagnosed patients. Expected graduation - Fall 2017
8/2014 - Present
- Master's Thesis Committee Member, Ankur Dashputre (Duquesne University). Cirrhosis and its complications: EMR analysis. Expected graduation - Summer 2016 [PhD student at the Institute of Health Outcomes and Policy program, University of Tennessee Health Science Center]
8/2013 - Present
- Master's Thesis Committee Chair, Somraj Ghosh (Duquesne University). Role of Statins in Chronic Obstructive Pulmonary Disease. Expected graduation - Summer 2016 [PhD student at the Health Outcomes program, University of Texas at Austin College of Pharmacy]
PAST GRADUATE ADVISEES
- Master's Thesis Committee Chair, Mousam Parekh (Duquesne University). Economic and humanistic impact of new treatments in hepatitis C. Expected graduation - Fall 2015 [Accepted as a Ph.D. Student at University of Maryland School of Pharmacy]
- Master's Thesis Committee Chair, Rahul Khairnar (Duquesne University). Barriers to Self-Management of Diabetes - Patient and Physician Perspectives. Expected graduation - 2015 [Ph.D. Student at University of Maryland School of Pharmacy]
- Master's Thesis Committee Member, Darshini Shah (Duquesne University). Outcomes Research in Young School Age Children with Autistic Disorder. Expected graduation - Spring 2015 [Analyst at LA-SER Group, New York]
- Master's Thesis Committee Member, Corry Bondi (Duquesne University). Association of Mental illness and Melatonin. Expected graduation - Fall 2015
- Master's Thesis Committee Chair, Rachi Parekh (Duquesne University). A comprehensive cost evaluation of Hospice Care. May 2013. [Past Position:Analyst, Managed Health Care Associates]
- Master's Thesis Committee Chair, Ishveen Chopra (Duquesne University). Association between obesity and therapeutic goal attainment in patients with concomitant hypertension and hyperlipidemia: Analysis using primary care electronic medical records database. August 2012.[Ph.D. Student at West Virginia University School of Pharmacy]
- Master's Thesis Committee Chair, Nipun Atreja (Duquesne University). Medication expenditure and resource utilization among patients with musculoskeletal disorders: Analysis of 2007 MEPS data. May 2012. [Ph.D. Student at University of Houston College of Pharmacy]
- Master's Thesis Committee Chair, Bhavini Patel (Duquesne University). Resource utilization among COPD and asthma patients. Analysis of 2007 MEPS data. May 2012.[Current Position: PRO specialist, Genentech; Past: Rutgers University Fellow, Worldwide Health Outcomes, Value, and Access at Novartis, Oncology]
- Doctoral Dissertation Committee Member, Phillip Lunney (Duquesne University). Improvement of release criteria for pharmaceutical solid dosage forms. August 2010. [Manager of Process Development for Plextronics, Inc., Pittsburgh]
- Fellowship Committee Member, David Ombengi (Duquesne University). Determine the quality of antihypertensive care provided by physicians and assess the factors associated with lack of uniform implementation of JNC7 guidelines for effective management of systolic hypertension (SH) in patients aged 50 years and older. July 2010. [Assistant Professor, Interim Director, Drug Information Center, Department of Pharmacy Practice, Hampton University School of Pharmacy]
- Master's Thesis Committee Chair, Pallavi Rane (Duquesne University). Hospital resource utilization among patients with Chronic Obstructive Pulmonary Disease - An analysis of 2002-2005 Healthcare Cost and Utilization Project Data. May 2010. [Current Position: Bayer Post-Doctoral Research Fellow at Tufts Medical Center, Boston]
- Master's Thesis Committee Chair, Hemangi Parekh (Duquesne University). Resource utilization among inpatients with Rheumatoid Arthritis - An analysis of 2002-2004 Healthcare Cost and Utilization Project data. May 2008. [Project manager, Health Economics & Outcomes at OptumInsight]
- Fellowship Committee Member, Tracy King (Duquesne University). Utility of Morinda Citrifolia as CAM therapy in the prevention and development of Metastatic Breast Cancer in vivo using the neu mouse model, May 2008. [Past Position: Portfolio Coordinator, Duquesne University School of Pharmacy]
- Master's Thesis Committee Chair, Shalini Naik (Duquesne University). Evaluating thecost-effectiveness of tiotropium in the treatment of Chronic Obstructive Pulmonary Disease. May 2007. [Staff Pharmacist; Past: Research Associate, Mapi Values]
- Master's Thesis Committee Member, Rahul Khanna (West Virginia University). Physician readiness to track body mass index (BMI) and counsel on physical activity among overweight and obese pediatric and adolescent patients. May 2007. [Assistant Professor at the University of Mississippi School of Pharmacy]
CURRENT FELLOWSHIP/RESIDENT ADVISEES
- Committee Member, Katlyn Simmons, Pharm.D. (2016-17) The Impact of a Pharmacy Resident's Intervention(s) on Blood Pressure Control in Patients with Diabetes and Uncontrolled Hypertension
- Committee Member, Teresina Imborgno, Pharm.D. (2016-17) Economic Impact of Patient-Centered Pharmacy Services in Long Term Care
CURRENT PHARM.D. ADVISEES (Health Economics and Outcomes Research Track)
- Brianna Cauley (Pharm.D., 2018): Patient reported outcomes instruments in clinical practice.
- Sha-Phawn Williams (Pharm.D., 2017): Patient reported outcomes instruments in clinical practice.
- Andrew Gaiser (Pharm.D., 2017): Ethical and economic perspectives regarding coverage policies related to expanded naloxone access efforts.
- Kaysee Gruss (Pharm.D., 2017): Clinical inertia in primary care practice - A review.
- Erica Loadman (Pharm.D., 2017): Monetary costs of multiple medication use for the treatment of individuals in recovery from chemical dependency.
PAST PHARM.D. ADVISEEPAST PHARM.D. ADVISEES (Health Economics and Outcomes Research Track)
- Lindsey Sosnowski (Pharm.D., 2016): Young-onset Parkinson's disease and quality of life [Merck Fellow, Global Medical Affairs in Oncology]
- Anastasia Ipatova (Pharm.D., 2016): Cystic fibrosis and quality of life [Walgreens Specialty PGY1 Residency]
- Taylor Price (Pharm.D., 2015): Pharmacoeconomics of chronotherapy [Current Position: Pharmacist, CVS Health]
- Kaitlyn Stroyne (Pharm.D., 2014). Predicating immunogenicity of infliximab: pharmacoeconomic implications for biosimilars [Clinical Advisor, Health Plan Clinical Account Services, CVS Health, Pittsburgh]
- Sara Barna (Pharm.D., 2014). Hematologic/Oncology FDA-Approved Products in 2013 [Pursuing Dental program at University of Pittsburgh]
- Katherine Gorcyca (Pharm.D., 2012). Estimating the value of rheumatoid arthritis education and management services in a specialty pharmacy. [Current Position: Manager, Global HEOR, Sanofi; Past: Fellow at Sanofi/Rutgers, Bridgewater, NJ 2012-2014]
- Lauren Pusateri (Pharm.D., 2012). Estimating the burden of rheumatoid arthritis on patients' work productivity [Current Position: Senior Pharmacist at Highmark Inc, Pittsburgh; Past: Clinical Outreach Pharmacist at Catamaran; Resident at RegenceRx, Portland, OR 2012-2013]
- Erin Henlyshyn (Pharm.D., 2010). Pulmonary rehabilitation: A budget impact model to evaluate how policy changes will impact reimbursement from a managed care perspective. [Current Position: Associate Director, Global Outcomes Research, Takeda; Past: Fellow at Xcenda, Tampa, FL 2010-2012]
- Kellie Dudash (Pharm.D., 2010). Use of tumor necrosis factor inhibitors in Ankylosing Spondylitis: A cost-effectiveness analysis and budget impact analysis. [Current Position: Analyst, Market Access, Xcenda; Past: Fellow at Thomas Jefferson, Philadelphia, PA 2010-2012]
PAST PHARM.D. ADVISEES (Research Mentor)
- Kemper May & Ryan Tercho (Pharm.D., 2016): A budget impact analysis of alirocumab in heterozygous familial hypercholesterolemia.
- Fennil Patel (Pharm.D., 2016): A systematic review of medical costs and cost-offsets for newly approved heart failure drug entresto®.
- Ashley Adams (2015): A pharmacoeconomic evaluation of enzalutamide in metastatic castration-resistant Prostate Cancer. Pharmacy Resident/M.S. Candidate at Michael E. DeBakey VA Medical Center, Houston, TX.
- Andrew Uhlmann (Pharm.D., 2014). Cost effectiveness of dimethyl fumarate in patients with relapsing-remitting multiple sclerosis.
Mukherjee K, Kamal KM. Socio-demographic Determinants of Out-of-Pocket Expenditure for Prescription Drugs in Rheumatoid Arthritis. American Health & Drug Benefits [Accepted].
Dashputre A, Kamal KM, Pawar G. Cost-effectiveness of peginterferon β-1a and alemtuzumab in relapsing remitting multiple sclerosis. Journal of Managed Care & Specialty Pharmacy [Accepted]
Kamal KM, Covvey J, Dashputre A, Ghosh S, Shah S, Bhosle M, Zacker C. A systematic review of the impact of cancer treatment on work productivity of patients and caregivers. Journal of Managed Care &
Specialty Pharmacy; 2017; 23(2):136-62
Trombatt W, Koerner P, Craft Z, Miller R, Kamal KM. Retrospective analysis of the medication utilization and clinical outcomes of patients treated with various regimens for hepatitis C infection. Journal of Pharmacy Practice, 2016.
Bhattacharya R, Kamal KM. Budget impact analysis of tofacitinib for treatment of rheumatoid arthritis. Journal of Arthritis [Accepted - Journal of Arthritis, 2015:4(2)]
Bondi CD, Khairnar RR, Kamal KM, Witt-Enderby P. An early development budget impact
model for the use of melatonin in the treatment and prevention of osteoporosis. Clinical Pharmacology & Biopharmaceutics. 2015;4(1).
Elliott J, Cherpes G, Kamal KM, Chopra I, Kalarchian M, Harrison C, Reidy M, Herk B,
McCrossin M. The relationship between antipsychotics and weight in patients with Prader-Willi Syndrome. Pharmacotherapy 2015;35(3):260-8.
Chiumente M, Gianino M, Minniti D, Mattei T, Spass B, Kamal KM, Zimmerman DE, Muca A,
Luda E. Burden of stroke in Italy: an economic model highlights savings arising from reduced disability following thrombolysis. International Journal of Stroke. 2015 Apr 8. doi: 10.1111/ijs.12481.
Giannetti VJ, Kamal KM. Adherence with Therapeutic Regimens: Behavioral and Pharmacoeconomic perspectives. J Pharm Pract. 2014 Oct 6. pii: 0897190014549840.
Kamal KM, Chopra I, Elliott J, Mattei T. Use of electronic medical records for clinical research in the management of type 2 diabetes. Research in Social Administrative Pharmacy, 2014: 10:877-884.
Chopra I, Kamal, KM. Factors associated with therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia. Hospital Practice. 2014: 42(2):77-88.
Chopra I, Kamal KM, Candrilli SD, Kanyongo G. Association between obesity and therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia. Postgraduate Medicine. 2014;126(1):66-77.
Chopra I, Kamal KM, Candrilli S. Variations in blood pressure and lipid goal attainment in primary care. Current Medical Research and Opinion. 2013. 29(9): 1115-1125
Chopra I, Kamal KM, Sankaranarayanan J. Factors associated with primary hip arthroplasty after hip fracture in United States. The American Journal of Managed Care. 2013;19(3):e74-e84.
Kamal KM, Zacker C, Civitarese L. Switching between different angiotensin receptor blockers (ARBs) in patients with controlled BP. American Journal of Pharmacy Benefits, 2012, 4(4):e81-e87.
Chopra I, Kamal KM. A systematic review of quality of life instruments in long-term breast cancer survivors. Health and Quality of Life Outcomes 2012, 10:14 (31 January 2012)
Naik S, Kamal KM, Keys PA, Mattei TJ. Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of Chronic Obstructive Pulmonary Disease. ClinicoEconomics and Outcomes Research, 2010; 2: 25-36.
Yoder JL, Kamal KM. A systematic review of economic analyses studying rituximab in R-CHOP therapy in patients with Non-Hodgkin Lymphoma. The Open Cancer Immunology Journal, 2009, 2:1-9.
Kamal KM, Desselle S, Rane P, Parekh R, Zacker C. Content analysis of FDA warning letters to manufacturers of pharmaceuticals and biologics. Drug Information Journal. 2009;43(4):385-393.
Khanna R, Scott VG, Kavookjian J, Kamal KM, Miller LA, Neal WA. Using the Theory of Reasoned Action to determine physicians' intention to measure body mass index in children and adolescents. Research in Social and Administrative Pharmacy. 2009;5(2): 170-81.
Kamal KM. Treating Crohn's Disease in the 21st Century: An evidence-based review of the management of refractory disease. First Report® March 2007. Invited submission for Continuing Medical Education sponsored by University of Cincinnati and Princeton Media Associates.
Kamal KM, Madhavan SS, Hornsby JA, Miller LA, Scott V, Kavookjian J. US rheumatologists' prescribing practices for anti-TNF agents. Published as an abstract in the 'Research Highlights' section of Nature Clinical Practice Rheumatology 2007;3(4):196-197.
Kamal KM, Madhavan SS, Hornsby JA, Miller LA, Scott V, Kavookjian J. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: A national survey of practicing United States rheumatologists. Joint Bone Spine, 2006;73 (6):718-724. Also, published in Revue du Rhumatisme, 2006; 73(12):1387-94 (French).
Kamal KM, Miller LA, Kavookjian J, Madhavan SS. Alternative decision analysis modeling in the economic evaluation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2006:36(1):50-60.
Tompkins NO, Kamal KM, Chapman D. West Virginia health education assessment project. Journal of School Health 2005;75(6):193-198.
Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal KM. Asthma hospitalization risk and costs for patients treated with fluticasone propionate versus montelukast. Annals of Asthma, Allergy and Immunology 2004;92:523-529.
Dino GA, Kamal KM, Kalsekar ID, Fernandes AW, Horn KA. Stages of change and smoking cessation outcomes in adolescents. Addictive Behavior 2004;29(5):935-40.
Kamal KM, Madhavan SS, Maine LL. Pharmacy and immunization services: Pharmacists' participation and impact. Journal of American Pharmacists Association 2003;43(4):470-82.
Kamal KM, Madhavan SS, Amonkar MM. Determinants of adult influenza and pneumonia immunization rates. Journal of American Pharmacists Association 2003;43(3):403-11.
Kamal KM, Madhavan SS, Maine LL. Pharmacists and immunization services: Impact of American Pharmaceutical Association's (APhA) Immunization Training Certification Program. American Journal of Pharmacists Education 2003;67(4):article 124.
Nair AM, Mungantiwar AA, Kamal KM, Saraf MN. Modulation of invitro anaphylaxis by furosemide. Indian Journal of Pharmacology 1997;29:182-186.
Nair AM, Mungantiwar AA, Kamal KM, Saraf MN. Antiallergic potential of furosemide. Indian Journal of Experimental Biology 1997;35:466-469.
Kamal KM. Community Pharmacy in the United States. In: Okada H and Kotani K, eds. Public Health in the 21st Century: Community Pharmacy - An International Comparison. Nova Science Publishers, New York: 2016:11-24.
Kamal KM. Operationalizing Research. In: Aparasu R, ed. Research Methods for Pharmaceutical Practice and Policy. Royal Pharmaceutical Society of Great Britain (Pharmaceutical Press): 2010:37-52.
- Westrick SC, Kamal KM, Moczygemba LR, Breland ML, Heaton PC. Characteristics of Social and Administrative Sciences Programs and Strategies for Student Recruitment and Development. Research in Social and Administrative Pharmacy. 2013;9:101-107.
- Elliot J, Koerner P, Heasley J, Kamal KM. Enhancing student learning of pediatrics through the use of active learning strategies. American Journal of Pharmaceutical Education. 2012;76(1).
- Surratt CK, Kamal KM, Wildfong PD. Research funding expectations as a function of faculty teaching/administrative workload. Research in Social and Administrative Pharmacy. 2011;7(2):192-201. Epub 2010 Jul 23.
- Kamal KM, Sakamaki A, Bricker JD, Kawasaki K. An elective course in pharmacoeconomics for pharmacy students in Japan - A transcultural experience. Currents in Pharmacy Teaching and Learning. 2010; 2:218-227.
- Skomo M, Kamal KM, Berdine H. A required course in the development, implementation and evaluation of clinical pharmacy services. American Journal of Pharmaceutical Education. 2008; 72(5):109.
Kamal KM. Identifying Contemporary, Relevant and Practical Research Questions. American Society of Health-System Pharmacists (ASHP) Foundation Resident Research Webinar Series "Essentials of Practice-Based Research for Pharmacists," May 2016.
GRANTS AND CONTRACTS (FUNDED)
|The impact of cancer treatment on work productivity in patients and caregivers: A review of the evidence||$46,950||Novartis||PI||2015 - 16|
|The impact of pharmacy clinical services on patient health||$2,500||National Association of Chain Drug Stores (NACDS) Academic Scholarship Program||Co-I/Mentor||2015|
|Impact of Rheumatoid arthritis on work productivity, disease severity, and adherence||$5,000||DU Presidential Scholarship Award||PI||2015|
|Primary Care Physician Adherence to Clinical Guidelines in Chronic Pain||$3,000||DU Chronic Pain Consortium||Co-PI||2014|
|The patient perception of a formal community pharmacy medication refill synchronization program and the impact of their overall health||$2,500||National Association of Chain Drug Stores (NACDS) Academic Scholarship Program||Co-I/Mentor||2014|
|Budget impact analysis of melatonin in the
prevention or treatment of osteoporosis
|$11,390||DU Mylan School of Pharmacy and the
Graduate School of Pharmaceutical Sciences
Interdisciplinary Research Program
|Metabolic risks associated with
antipsychotic medications in Prader
|$10,697||Prader Willi Syndrome Association||Co-I||2012|
|Examining the consequences of multiple sclerosis
from a patient
|Economic and humanistic outcomes in patients
with advanced renal cell carcinoma
|$7,000||Arnold Consultancy & Technology, LLC,
|Non-medical switching between different ARBs
on continuity of care and BP control
|Quality improvement in physician process and
patient outcomes in diabetes care.
|$5,000||DU Presidential Scholarship Award||PI||2008-09|
|Pharmacoeconomic evaluation of TNF
inhibitors in AS
|$9,887||DU Faculty Development Fund||PI||2007-10|
|Consequences of pharmacy benefits design||$22,696||Novartis||Co-I||2006-07|
|Content analysis of FDA warning letters to manufacturers.||$7,389||Novartis||Co-I||2006-07|
- Kamal KM. Nominated by Duquesne University School of Pharmacy for Duquesne University President's Faculty Award for Excellence in Teaching: 2016.
- Trombatt W, Koerner P, Craft Z, Miller R, Kamal KM. Retrospective analysis of the medication utilization and clinical outcomes of patients treated with various regimens for hepatitis C infection. Won the Top Poster award at the 2015 Annual Meeting & Expo of National Association of Specialty Pharmacy, September 29-October 1, 2015 at National Harbor, MD.
- Thornton J, Kamal KM. Chronotherapy strategies in patients with hypertension versus standard of care. Regional Pharmacy Research Forum, Area of Disease and Health, First Place Poster Award. West Virginia University, June 2015.
- Sosnowski L, Kamal KM. Impact of young-onset Parkinson's disease on quality of life - A literature review. Gumberg Library Award at Undergraduate Research Symposium, Duquesne University, April 2015.
- Bhattacharya R, Kamal KM. Budget impact analysis of Tofacitinib for treatment of rheumatoid arthritis. Won second prize in the student presentation category at the annual meeting of Drug Information Association (DIA), San Diego, June 2014.
- Gaiser A, Kamal KM, Joseph Cimakasky. Andrew Gaiser received the Liberal Arts Endowed Fellow Award. In conjunction with the award, Andrew received additional funding to travel to Japan on a study abroad trip to further his research study "A sociohistorical analysis of the proclivities of Japanese and American populations towards health care systems and policies" April 2014.
- Cherpes G, Elliott JP, Kamal K, Bunk E, Cockroft M, Marini R, Modany A, Chopra I. The effect of atypical antipsychotic medications on body temperature in patients with Prader-Willi Syndrome. Won the Mylan School of Pharmacy Award for Undergraduate Research at the Duquesne University 6th Annual Research Symposium in Pittsburgh, PA, April 2014.
- Mylan School of Pharmacy's Faculty Award for outstanding contributions in teaching, service, and scholarship, 2010
- Nominated by Duquesne University Mylan School of Pharmacy for Duquesne University President's Faculty Award for Excellence in Scholarship: 2011 and 2010
- Dudash K, Kamal KM. Use of tumor necrosis factor inhibitors in Ankylosing Spondylitis: A cost-effectiveness analysis and budget impact analysis. Selected as the best paper in the Student/Fellows/Residents presentation category at the annual meeting of Academy of Managed Care Pharmacy (AMCP), San Diego, April 2010
- Khanna R, Kamal KM, Smith M. Utilization and costs of drugs and office services among recipients of Medicaid with rheumatoid arthritis with versus without comorbid depression. Association of Rheumatology Health Professionals Graduate Student Award, 2006
- Graduate Research Award, School of Pharmacy, West Virginia University, 2001-02
- All India Council of Technical Education Junior Research Fellowship, 1994-96
- International Society for Pharmacoeconomics & Outcomes Research (ISPOR): 2000 - Present
- Academy of Managed Care Pharmacy (AMCP): 2012 - Present
- American Association of Colleges of Pharmacy (AACP): 2006 - Present
- Association of Rheumatology Health Professionals (ARHP): 2006, 2007
- Society for Medical Decision Making (SMDM): 2006, 2007
- Rho Chi Honor Society: 2000 - Present
- Co-Chair: Oncology Special Interest Group (International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
SIG charge: Develop best practices in modeling health technologies in oncology